RXi Pharmaceuticals
Written by
RXi Pharmaceuticals |
Expanding into immuno-oncology |
Acquisition announcement |
Pharma & biotech |
25 October 2016 |
Share price performance
Business description
Next events
Analysts
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
RXi recently announced that it has entered into an exclusive option agreement to acquire MirImmune, an early-stage private company focusing on immune checkpoint modulation, in exchange for a share amount equal to 19.99% of RXi’s outstanding stock plus milestones. MirImmune had previously licensed RXi’s sd-rxRNA technology in March 2015 and has since selected six lead compounds, which will be used alone or in combination to develop cell therapy to treat cancer. The first cell therapy will likely reach the clinic in 2018. RXi also announced a planned capital raise. If unable to raise capital, its cash runway extends only into Q217.
Year |
Revenue ($m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/14 |
0.1 |
(7.0) |
(4.25) |
0.0 |
N/A |
N/A |
12/15 |
0.0 |
(8.5) |
(1.70) |
0.0 |
N/A |
N/A |
12/16e |
0.0 |
(7.7) |
(1.17) |
0.0 |
N/A |
N/A |
12/17e |
0.0 |
(11.1) |
(1.62) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortization of acquired intangibles, exceptional items and share-based payments.
A new approach using validated targets
MirImmune had been focusing on developing sd-rxRNA compounds that target, among others, PD-1 and CTLA4, which have been validated by currently marketed compounds such as Keytruda (anti-PD-1) and Yervoy (anti-CTLA4). It has also demonstrated preclinically that CAR-T cells modified with anti-PD-1 targeted sd-rxRNA can significantly slow tumor growth in an ovarian cancer mouse model.
An attractively priced asset
MirImmune was founded in 2014 (co-founded by Tim Barberich, former chairman and CEO of Sepracor, which was sold in 2009 for $2.6bn) and is closely held, having yet to obtain VC funding. At current market valuations, it will be acquired for $2m upfront, putting the per-compound figure close to academic license levels.
Late-2016 and 2017 filled with potential catalysts
Data for RXi’s lead compound RXI-109, an sd-rxRNA compound targeting CTGF, being studied in Phase I/II for the prevention of retinal scarring and in Phase II for the prevention of dermal scarring, should start reading out later this year, with more complete data available in 2017. Also, the Phase IIa trial of Samcyprone in warts is expected to be fully enrolled and have initial data read-outs by the end of the year.
Valuation: $17.57 per share
We have increased our valuation slightly to $115.3m or $17.57 per basic share, from $111.5m or $17.06 per basic share, mainly due to rolling forward our NPV by a quarter. RXi announced a planned capital raise in order to fund both its current and acquired pipeline and we calculate a funding need of $20m through 2017 (cash as of 30 September was $4.4m). Given current share levels and the unfriendly fund-raising environment, an equity raise of that magnitude could lead to very significant dilution of existing shareholders and is not taken into account in our NPV value.
A potentially inexpensive route into a high-value area
RXi has announced that it has entered into an exclusive option agreement to acquire MirImmune, a small, closely-held private company founded in 2014, for a share amount equal to 19.99% of the RXi common stock outstanding at the time of the close, plus certain undisclosed milestones. The option can be exercised any time prior to April 5, 2017 and we believe it will be consummated once RXi raises additional capital (the company also announced it is planning an offering in a separate press release).
MirImmune had licensed RXi’s sd-rxRNA technology for use in cell-based cancer immunotherapy back in March 2015, in exchange for single-digit royalties, milestone payments, small annual fees and the right for RXi to acquire a double-digit stake. MirImmune had been focusing on developing compounds that hit a variety of targets, including PD-1 and CTLA4, which have been validated by currently marketed blockbuster compounds such as Keytruda (anti-PD-1) and Yervoy (anti-CTLA4). The knockdown of these proteins should enable the CAR-T cells to recognize and engage tumor cells that are otherwise masked from the immune system via expression of checkpoint ligands (for instance PD-L1 or CD80).
Since licensing RXi’s technology, MirImmune has selected six lead compounds against different extracellular and intracellular immune checkpoints. It also demonstrated the silencing of all six targets in preclinical studies both singly and in combination (see Exhibit 1). The ability to simultaneously silence multiple checkpoint genes and to target intracellular targets which antibodies cannot reach could be a competitive advantage.
|
Exhibit 1: MirImmune data suggesting ability to target multiple immune checkpoints at the same time |
|
|
Source: RXi |
MirImmune has also shown that mesothelin-targeted CAR-T cells modified with anti-PD-1 targeted sd-rxRNA silences PD-1 and also significantly slows tumor growth in an ovarian cancer model (see Exhibits 2 and 3).
|
Exhibit 2: MirImmune data on PD-1 silencing |
Exhibit 3: MirImmune data demonstrating the gene silencing effect of CAR-T + anti-PD-1 sd-rxRNA |
|
|
|
Source: RXi |
RXi |
|
Exhibit 2: MirImmune data on PD-1 silencing |
|
|
Source: RXi |
|
Exhibit 3: MirImmune data demonstrating the gene silencing effect of CAR-T + anti-PD-1 sd-rxRNA |
|
|
RXi |
MirImmune’s cell therapy program is quite early stage and the first cell therapy will likely not enter the clinic until 2018. However, at a cost of ~$2m in equity, based on today’s share price, they are inexpensive and further development can enhance their value substantially. However, until the deal closes and they start entering the clinic, we will not be including the MirImmune programs in our valuation of the company.
Valuation
We have increased our valuation slightly to $115.3m or $17.57 per basic share, from $111.5m or $17.06 per basic share, mainly due to rolling forward our NPV by a quarter. The company has announced a capital raise in order to continue funding both its current and acquired pipeline and we calculate a funding need of $20m through 2017. Given current share levels and the unfriendly fund-raising environment, an equity raise of that magnitude could lead to very significant dilution of existing shareholders. For example, if RXi raises $20m at $1.00 per share, that would require the issuance of an additional 20m shares and would reduce our value to around $5 per basic share, and would practically be a recapitalization of the company.
Upcoming catalysts that could alter our valuation for the company will include data for lead compound RXI-109. It is being studied in a Phase I/II for the prevention of retinal scarring and in a Phase II for the prevention of dermal scarring, with readouts later this year and more complete data available in 2017 (assuming it successfully raises capital). We also expect news from Samcyprone, which is in a Phase IIa for the treatment of warts. Enrolment is expected to complete by the end of the year with interim data expected in the same timeframe. Full data from the trial is expected in H117.
Exhibit 4: RXi valuation
Product |
Launch |
Peak sales ($m) |
Risk adj. |
Royalty rate |
rNPV |
rNPV/share |
RX-109 scarring |
2021 |
1,453 |
20% |
17.5% |
78.4 |
11.95 |
RX-109 AMD |
2022 |
1,077 |
10% |
15% |
11.7 |
1.79 |
Samcyprone |
2020 |
177 |
40% |
17.5% |
17.7 |
2.70 |
RXI-231 and RXI185 |
2019 |
250 |
20% |
4.0% |
3.0 |
0.46 |
Implied enterprise value |
110.9 |
16.90 |
||||
Net cash (Sept 30) |
4.4 |
0.67 |
||||
Overall valuation |
115.3 |
17.57 |
Source: Edison Investment Research
Financials
As of the end of Q316, RXi had $4.4m in cash and equivalents, an amount it recently pre-announced at an investor presentation. Its quarterly cash burn is around $2m per quarter. As the company is making capital preservation a priority we have decreased our estimates for R&D spending in 2016 from $7.5m to $5.2m, a decrease from the $6.9m in R&D spending in 2015. Our 2017 estimates have also decreased from $10m in R&D spending to $7.5m. The company has announced it is currently in the process of planning a capital raise to fund both the development of its current pipeline and the compounds it will be acquiring from MirImmune. Although the company has never incurred debt, for illustrative purposes our forecasts currently include $10m in long-term debt in our model in each of 2016 and 2017, ie a $20m near-term funding requirement, mainly to cover expected R&D costs. Once both the capital raise and the MirImmune acquisition are finalized, we may revisit our spending estimates as the fresh capital and additional programs may accelerate spending.
Exhibit 5: Financial summary
$000s |
2013 |
2014 |
2015 |
2016e |
2017e |
||
Year end 31 December |
US GAAP |
US GAAP |
US GAAP |
US GAAP |
US GAAP |
||
PROFIT & LOSS |
|||||||
Revenue |
|
|
399 |
71 |
34 |
19 |
0 |
Cost of Sales |
0 |
0 |
0 |
0 |
0 |
||
Gross Profit |
399 |
71 |
34 |
19 |
0 |
||
Research and development |
(5,401) |
(5,680) |
(6,925) |
(5,201) |
(7,500) |
||
General & administrative |
(3,697) |
(3,217) |
(3,346) |
(3,517) |
(3,868) |
||
EBITDA |
|
|
(6,819) |
(7,067) |
(8,551) |
(7,779) |
(10,406) |
Operating Profit (before GW and except.) |
|
|
(6,720) |
(6,980) |
(8,474) |
(7,723) |
(10,374) |
Intangible Amortization |
0 |
0 |
0 |
0 |
0 |
||
Exceptionals/Other |
(12,250) |
0 |
(228) |
0 |
0 |
||
Share-based payments |
(1,979) |
(1,846) |
(1,535) |
(975) |
(995) |
||
Operating Profit |
(18,970) |
(6,980) |
(8,702) |
(7,723) |
(10,374) |
||
Net Interest |
24 |
17 |
14 |
18 |
(749) |
||
Other (includes change in fair value of warrants) |
0 |
9 |
0 |
7 |
0 |
||
Profit Before Tax (norm) |
|
|
(6,696) |
(6,954) |
(8,460) |
(7,705) |
(11,123) |
Profit Before Tax (FRS 3) |
|
|
(20,925) |
(8,800) |
(10,223) |
(8,680) |
(12,117) |
Tax |
0 |
0 |
0 |
0 |
0 |
||
Deferred tax |
0 |
0 |
0 |
0 |
0 |
||
Profit After Tax (norm) |
(6,696) |
(6,954) |
(8,460) |
(7,705) |
(11,123) |
||
Profit After Tax (FRS 3) |
(20,925) |
(8,800) |
(10,223) |
(8,680) |
(12,117) |
||
Average Number of Shares Outstanding (m) |
1.0 |
1.6 |
5.0 |
6.6 |
6.8 |
||
EPS - normalised fully diluted ($) |
|
|
(6.52) |
(4.25) |
(1.70) |
(1.17) |
(1.62) |
EPS - FRS 3 ($) |
|
|
(28.78) |
(7.90) |
(2.10) |
(1.32) |
(1.77) |
Dividend per share ($) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
195 |
201 |
181 |
134 |
102 |
Intangible Assets |
0 |
0 |
0 |
0 |
0 |
||
Tangible Assets |
177 |
183 |
163 |
107 |
75 |
||
Other |
18 |
18 |
18 |
27 |
27 |
||
Current Assets |
|
|
14,743 |
8,988 |
10,978 |
12,617 |
12,209 |
Stocks |
0 |
0 |
0 |
0 |
0 |
||
Debtors |
0 |
0 |
0 |
0 |
0 |
||
Cash |
14,440 |
8,546 |
10,667 |
12,140 |
11,732 |
||
Other |
303 |
442 |
311 |
477 |
477 |
||
Current Liabilities |
|
|
(2,076) |
(1,334) |
(2,269) |
(1,559) |
(2,243) |
Creditors |
(2,076) |
(1,334) |
(2,269) |
(1,559) |
(2,243) |
||
Short term borrowings |
0 |
0 |
0 |
0 |
0 |
||
Long Term Liabilities |
|
|
0 |
0 |
0 |
(10,000) |
(20,000) |
Long term borrowings |
0 |
0 |
0 |
(10,000) |
(20,000) |
||
Other long term liabilities |
0 |
0 |
0 |
0 |
0 |
||
Net Assets |
|
|
12,862 |
7,855 |
8,890 |
1,192 |
(9,932) |
CASH FLOW |
|||||||
Operating Cash Flow |
|
|
(6,311) |
(7,758) |
(7,317) |
(8,527) |
(10,407) |
Net Interest |
0 |
0 |
0 |
0 |
0 |
||
Tax |
0 |
0 |
0 |
0 |
0 |
||
Capex |
(78) |
(95) |
(57) |
0 |
0 |
||
Acquisitions/disposals |
0 |
12 |
0 |
0 |
0 |
||
Financing |
15,684 |
1,947 |
9,495 |
0 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
0 |
||
Other |
(35) |
0 |
0 |
0 |
0 |
||
Net Cash Flow |
9,260 |
(5,894) |
2,121 |
(8,527) |
(10,407) |
||
Opening net debt/(cash) |
|
|
(5,180) |
(14,440) |
(8,546) |
(10,667) |
(2,140) |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
||
Exchange rate movements |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
300 |
||
Closing net debt/(cash) |
|
|
(14,440) |
(8,546) |
(10,667) |
(2,140) |
7,968 |
Source: RXi Pharmaceuticals accounts, Edison Investment Research
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US |
Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia |
Wellington +64 (0)48 948 555 Level 15, 171 Featherston St Wellington 6011 New Zealand |
Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany |
London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom |
New York +1 646 653 7026 245 Park Avenue, 39th Floor 10167, New York US |
Sydney +61 (0)2 9258 1161 Level 25, Aurora Place 88 Phillip St, Sydney NSW 2000, Australia |
Wellington +64 (0)48 948 555 Level 15, 171 Featherston St Wellington 6011 New Zealand |